Why the study?
Does intravenous atropine sulfate cause adverse effects such as serious arrhythmias or increased ischemia in patients with myocardial infarction?
Does intravenous atropine sulfate cause adverse effects such as serious arrhythmias or increased ischemia in patients with myocardial infarction?
Atropine should be used cautiously during myocardial infarction due to the risk of serious arrhythmias and potential to increase ischemia.
Answers are grounded in this paper and cite their sources.
May support caution with atropine in MI; leaves open confirmation in human trials.
Intravenously administered atropine sulfate is commonly used for the control of bradycardias during myocardial infarction. There is increasing evidence that this may not be beneficial to the patient and that serious arrhythmias may be produced. Atropine has also been demonstrated to increase the area of ischemia during myocardial infarction in dogs, but this has not been well documented in humans. It is suggested that atropine be used cautiously during myocardial infarction, and only when the hemodynamic situation clearly warrants its use or when a serious cardiac arrhythmia exists. (JAMA228:1414-1416, 1974)
No takes yet. Share an insight, caveat, or question.
Sidney M. Richman (1974) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: